Physician profile
Aylin Perez
NPI 1881842623
$4,180.22
in general payments reported to CMS, 2019-2025
19 companies · $2,280 in 2025
The $2,280 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.09 · 2022: $169 · 2023: $412 · 2024: $1,245 · 2025: $2,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,935.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,827.49 | 2024-2025 | Apretude, Dovato, Rukobia |
| Gilead Sciences, INC. | $1,051.07 | 2024-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $258.77 | 2024-2025 | Pifeltro, Delstrigo, Capvaxive |
| Lilly USA, LLC | $239.21 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $204.84 | 2021-2024 | |
| Theratechnologies INC. | $121.51 | 2024-2025 | Egrifta, Trogarzo |
| Idorsia Pharmaceuticals US INC | $81.60 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $68.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Napo Pharmaceuticals INC | $40.47 | 2025 | Mytesi |
| Novo Nordisk INC | $39.51 | 2021-2024 | Rybelsus, Ozempic |
| Amgen INC. | $38.40 | 2022-2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $34.39 | 2022-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $31.40 | 2021-2023 | Eliquis |
| Abbvie INC. | $28.77 | 2024 | |
| Emd Serono, INC. | $28.34 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $25.67 | 2023 | Rexulti |
| Paratek Pharmaceuticals, INC. | $21.16 | 2025 | Nuzyra |
| Phadia US INC. | $19.98 | 2022 | |
| Lundbeck LLC | $19.57 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aylin Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.